Christine A. Poon

October 17, 2026

NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.

October 17, 2026

Prudential Financial faces negative S&P outlook and lower JP Morgan target. S&P has revised Prudential’s outlook to negative, citing headwinds in Japan. JP Morgan kept a neutral stance but lowered its price target to $127. PGIM, Prudential’s asset‑management arm, announced a merger of the Jennison Focused Value Fund into an ETF and a transfer of its Active High Yield Bond ETF listing to the Cboe BZX exchange. The stock is trading near its long‑standing support level of about $117.5.

October 17, 2026

Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.

October 9, 2026

Prudential Financial Discusses Japan Business Update After FSA Orders. Prudential Financial released a transcript of a discussion about its Japan operations. The company explained the steps it is taking after orders from the Financial Services Agency, including remediation measures and a plan for moving forward. These updates give investors a clearer view of how regulatory actions may affect the insurer’s business and its long‑term strategy.

October 17, 2026

SHW Benefits from Rotation to Consumer and Defensive Stocks. Recent market trading has shown a rotation out of technology stocks into consumer and defensive sectors, providing a lift to home improvement stocks like Sherwin-Williams. Commentary on the company indicates that its quality remains fairly priced amid this broader market shift. As a Dow Jones component, the stock is catching attention while market participants seek stability in defensive areas.